RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress

Core Insights - Roche announced new data from two studies on its ophthalmology drug Vabysmo, reinforcing its efficacy and safety in treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema [1][2] Group 1: Study Results - The AVONELLE-X study demonstrated that vision remained stable over two years, with nearly 80% of patients extending their treatment intervals to every three or four months by the end of the study [3][4] - The SALWEEN study showed Vabysmo resulted in significant vision gains and retinal drying in patients with polypoidal choroidal vasculopathy (PCV), with over 60% of patients experiencing complete resolution of lesions [5] Group 2: Financial Performance - Vabysmo's sales grew 18% to CHF 2.1 billion in the first half of 2025, driven by strong demand across all regions, contributing to Roche's overall sales growth [6] - Roche's Pharmaceuticals Division saw a 10% increase in sales to CHF 24 billion in the first half of 2025, supported by strong demand for key drugs including Vabysmo, Hemlibra, and Ocrevus [7] Group 3: Market Position - Roche's shares have increased by 25% year-to-date, significantly outperforming the industry average growth of 1.7% [8] - Vabysmo is positioned as a strong competitor to Regeneron's Eylea, which has faced declining sales, prompting Regeneron to develop a higher dose version [6]